Cargando…

Serum levels of interleukin-6 and Vitamin D at the onset of multiple sclerosis and neuromyelitis optica: A pilot study

BACKGROUND: Interleukin-6 (IL-6) is an important mediator in the acute phase of inflammatory diseases such as neuromyelitis optica (NMO) and multiple sclerosis (MS). The level of IL-6 is higher in cerebrospinal fluid and serum of NMO patients compare to MS. Vitamin D has a regulatory effect on IL-6,...

Descripción completa

Detalles Bibliográficos
Autores principales: Ashtari, Fereshteh, Madanian, Reyhanehsadat, Zarkesh, Sayyed Hamid, Ghalamkari, Arshia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9639709/
https://www.ncbi.nlm.nih.gov/pubmed/36353347
http://dx.doi.org/10.4103/jrms.jrms_796_21
_version_ 1784825695148441600
author Ashtari, Fereshteh
Madanian, Reyhanehsadat
Zarkesh, Sayyed Hamid
Ghalamkari, Arshia
author_facet Ashtari, Fereshteh
Madanian, Reyhanehsadat
Zarkesh, Sayyed Hamid
Ghalamkari, Arshia
author_sort Ashtari, Fereshteh
collection PubMed
description BACKGROUND: Interleukin-6 (IL-6) is an important mediator in the acute phase of inflammatory diseases such as neuromyelitis optica (NMO) and multiple sclerosis (MS). The level of IL-6 is higher in cerebrospinal fluid and serum of NMO patients compare to MS. Vitamin D has a regulatory effect on IL-6, so it may have a negative correlation with IL-6 in the acute phase of these diseases. This study was performed to evaluate the serum levels of IL-6 and Vitamin D in NMO and MS patients at the onset of disease to find differences that may help in early diagnosis. MATERIALS AND METHODS: This case–control study was done on patients with the first episode of optic neuritis, transverse myelitis, and area postrema syndrome who were referred to Kashani MS Center in Isfahan, Iran, between January 2018 and January 2020. The serum levels of Vitamin D and IL-6 were assessed using enzyme-linked immunosorbent assay in blood sample taken at the time of first presentation in patients who had a definitive diagnosis of NMO and MS during subsequent workup. RESULTS: During a 2-year follow-up, definitive diagnosis of NMO was given in 25 cases, and they were compared with 25 cases that were randomly selected from patients with definite MS. Nineteen patients in the NMO group and 21 patients in the MS group were female. The mean age of patients in the NMO and MS groups was 29.64 ± 1.47 and 30.20 ± 1.42, respectively (P = 0.46). The mean of serum level of Vitamin D was 24.88 ± 15.2 in NMO patients and 21.56 ± 18.7 in MS patients without significant difference (P = 0.48). The mean of IL-6 was 30.1 ± 22.62 in the NMO group and 23.35 ± 18.8 in the MS group without significant difference (P = 0.28). The serum levels of Vitamin D were insufficient in both groups. No correlation between Vitamin D and IL-6 levels was found in our study (P > 0.05). CONCLUSION: Our results showed that serum IL-6 levels were higher at the onset of NMO disease compared with MS. The serum levels of Vitamin D were low in both groups and there was no association between serum levels of Vitamin D and IL-6 in either group. Future studies with large sample size are needed to confirm these findings.
format Online
Article
Text
id pubmed-9639709
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-96397092022-11-08 Serum levels of interleukin-6 and Vitamin D at the onset of multiple sclerosis and neuromyelitis optica: A pilot study Ashtari, Fereshteh Madanian, Reyhanehsadat Zarkesh, Sayyed Hamid Ghalamkari, Arshia J Res Med Sci Original Article BACKGROUND: Interleukin-6 (IL-6) is an important mediator in the acute phase of inflammatory diseases such as neuromyelitis optica (NMO) and multiple sclerosis (MS). The level of IL-6 is higher in cerebrospinal fluid and serum of NMO patients compare to MS. Vitamin D has a regulatory effect on IL-6, so it may have a negative correlation with IL-6 in the acute phase of these diseases. This study was performed to evaluate the serum levels of IL-6 and Vitamin D in NMO and MS patients at the onset of disease to find differences that may help in early diagnosis. MATERIALS AND METHODS: This case–control study was done on patients with the first episode of optic neuritis, transverse myelitis, and area postrema syndrome who were referred to Kashani MS Center in Isfahan, Iran, between January 2018 and January 2020. The serum levels of Vitamin D and IL-6 were assessed using enzyme-linked immunosorbent assay in blood sample taken at the time of first presentation in patients who had a definitive diagnosis of NMO and MS during subsequent workup. RESULTS: During a 2-year follow-up, definitive diagnosis of NMO was given in 25 cases, and they were compared with 25 cases that were randomly selected from patients with definite MS. Nineteen patients in the NMO group and 21 patients in the MS group were female. The mean age of patients in the NMO and MS groups was 29.64 ± 1.47 and 30.20 ± 1.42, respectively (P = 0.46). The mean of serum level of Vitamin D was 24.88 ± 15.2 in NMO patients and 21.56 ± 18.7 in MS patients without significant difference (P = 0.48). The mean of IL-6 was 30.1 ± 22.62 in the NMO group and 23.35 ± 18.8 in the MS group without significant difference (P = 0.28). The serum levels of Vitamin D were insufficient in both groups. No correlation between Vitamin D and IL-6 levels was found in our study (P > 0.05). CONCLUSION: Our results showed that serum IL-6 levels were higher at the onset of NMO disease compared with MS. The serum levels of Vitamin D were low in both groups and there was no association between serum levels of Vitamin D and IL-6 in either group. Future studies with large sample size are needed to confirm these findings. Wolters Kluwer - Medknow 2022-09-27 /pmc/articles/PMC9639709/ /pubmed/36353347 http://dx.doi.org/10.4103/jrms.jrms_796_21 Text en Copyright: © 2022 Journal of Research in Medical Sciences https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Original Article
Ashtari, Fereshteh
Madanian, Reyhanehsadat
Zarkesh, Sayyed Hamid
Ghalamkari, Arshia
Serum levels of interleukin-6 and Vitamin D at the onset of multiple sclerosis and neuromyelitis optica: A pilot study
title Serum levels of interleukin-6 and Vitamin D at the onset of multiple sclerosis and neuromyelitis optica: A pilot study
title_full Serum levels of interleukin-6 and Vitamin D at the onset of multiple sclerosis and neuromyelitis optica: A pilot study
title_fullStr Serum levels of interleukin-6 and Vitamin D at the onset of multiple sclerosis and neuromyelitis optica: A pilot study
title_full_unstemmed Serum levels of interleukin-6 and Vitamin D at the onset of multiple sclerosis and neuromyelitis optica: A pilot study
title_short Serum levels of interleukin-6 and Vitamin D at the onset of multiple sclerosis and neuromyelitis optica: A pilot study
title_sort serum levels of interleukin-6 and vitamin d at the onset of multiple sclerosis and neuromyelitis optica: a pilot study
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9639709/
https://www.ncbi.nlm.nih.gov/pubmed/36353347
http://dx.doi.org/10.4103/jrms.jrms_796_21
work_keys_str_mv AT ashtarifereshteh serumlevelsofinterleukin6andvitamindattheonsetofmultiplesclerosisandneuromyelitisopticaapilotstudy
AT madanianreyhanehsadat serumlevelsofinterleukin6andvitamindattheonsetofmultiplesclerosisandneuromyelitisopticaapilotstudy
AT zarkeshsayyedhamid serumlevelsofinterleukin6andvitamindattheonsetofmultiplesclerosisandneuromyelitisopticaapilotstudy
AT ghalamkariarshia serumlevelsofinterleukin6andvitamindattheonsetofmultiplesclerosisandneuromyelitisopticaapilotstudy